Celgene Secures Revlimid Frontline Myeloma Approval
Executive Summary
Labeling includes new warning for development of second primary malignancies and more language about other kinds of adverse events, but there is already widespread off-label use and analysts don’t expect the warnings to have much impact.
You may also be interested in...
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
Revlimid’s New Label Features New Safety Language
Labeling for newly diagnosed multiple myeloma includes new warning on risk of second primary malignancies, among other changes.
Celgene Pulls Back From First-Line CLL As Revlimid ORIGIN Trial Terminates
Imbalance of deaths for Revlimid in the ORIGIN treatment-naïve CLL study could be due to the advanced age of participants or their many comorbidities. Future of drug as monotherapy in treatment-naïve patients is now unlikely, but studies in later lines of treatment go on.